CORRESPONDENCE

Reply to: Peak Corticosteroid Dose for Immune-Related Adverse Events and Survival: Not the Whole Story

Rik J. Verheijden, MSc, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Jolien S. de Groot, MD, PhD, Babs O. Fabriek, PhD, and Miki N. Hew, MD, PhD, Medicines Evaluation Board, Utrecht, the Netherlands; Anne M. May, PhD, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; and Karijn P.M. Suijkerbuijk, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands

Corresponding author: Karijn P.M. Suijkerbuijk, MD, PhD; e-mail: [email protected].

Journal of Clinical Oncology 43(5):p 616-619, February 10, 2025. | DOI: 10.1200/JCO-24-02234